CTOs on the Move

Werewolf Therapeutics

www.werewolftx.com

 
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body`s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.werewolftx.com
  • 1030 Massachusetts Avenue Suite 210
    Cambridge, MA USA 02138
  • Phone: n/a

Executives

Name Title Contact Details
Chulani Karunatilake
Chief Technology Officer Profile

Funding

Werewolf Therapeutics raised $56M on 11/20/2019

Similar Companies

Quentis Therapeutics

Quentis is at the forefront of the next generation of immuno-oncology companies that are translating novel biology into new therapeutic approaches to help more patients benefit from immunotherapy.

TissueVision

TissueVision Inc. (TVI) is a multi-disciplinary life sciences company offering 3D tissue imaging and analysis solutions for the research market. Our powerful Serial Two-Photon Plus (STP²) platform features stunning high-resolution multispectral datasets and analysis pipelines that create reliable 3D tissue models. The indexed histological sections produced during the STP² process can be further investigated with secondary analyses that run the gamut from standard histological stains to advanced spatial genomics. The final result is rich, multiplexed 3D models that deliver actionable and quantitative results. TVI provides project design, GLP-like documentation, including full protocol and report generation, and quality control review measures of all study-related materials. TVI is a solution provider to help answer research questions in a variety of therapeutic areas, including neuroscience, cancer, neurodegeneration, ophthalmology, and dermatology.

Memphis Bio Works

Memphis Bio Works is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Palvella Therapeutics

Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.

Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.